Understanding FABP5 in COPD Flares
Official title: Role of FABP5 in COPD Exacerbations
Funded at National Jewish Health · NIH-11145913 · Data updated 2026-11-12
This research explores how a protein called FABP5 influences lung inflammation in people with chronic obstructive pulmonary disease, or COPD.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | National Jewish Health NIH-funded |
| Lab location | 1 site (Denver, United States) |
| Project start | June 15, 2019 |
| Project end | June 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $591,985 |
| NIH project number | 5R01HL141264-06 |
| Project ID | NIH-11145913 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with chronic obstructive pulmonary disease (COPD), particularly those who experience frequent lung inflammation and exacerbations, are the focus of this research.
✕Less likely to help
Individuals without COPD or chronic lung inflammation would not directly benefit from this specific research.
What this research studies
We know that inflammation plays a big part in many lung conditions, especially COPD, where repeated infections can lead to severe flare-ups. Our bodies have special immune cells called macrophages in the lungs that are key to controlling this inflammation. These cells can either promote inflammation or help repair tissues, and their function is guided by their internal programming. This project aims to understand how a specific protein, FABP5, and its interaction with another protein, PPARγ, guide these macrophages to help resolve inflammation and prevent COPD flares. We are also looking at a genetic difference that might be linked to these flare-ups.
Why it matters
Potential benefit: If successful, this work could lead to new ways to target inflammation and prevent severe flare-ups in people living with COPD.
How similar studies have gone: While previous work has identified FABP5's role in macrophage function and a genetic link to COPD exacerbations, the critical role of this specific protein interaction and genetic variation for therapeutic targeting is currently unknown.
Where this research is happening
-
National Jewish Health
Denver, United States Active
Researchers
- Principal investigator: Gally, Fabienne — National Jewish Health
- Study coordinator: Gally, Fabienne
Related research
Other NIH-funded projects on the same topics.
-
Omalizumab for COPD patients with allergen sensitization and exposure
A multicenter trial will test whether adding omalizumab helps people with COPD who are allergic to common indoor allergens and are exposed to them.
-
Clinical CT Imaging to identify and subtype pulmonary hypertension in COPD
A new CT imaging approach aims to help doctors detect and classify pulmonary hypertension in people with COPD.
-
Next-Generation Wearable AI for Precision COPD Risk and Care
A patient-centered project uses a smart wearable and AI to predict COPD flare-ups and support doctors in making better care decisions.
-
Ethics-aware Multimodal AI for COPD prevention, diagnosis, and treatment
A broad AI model uses diverse health data to help predict and manage COPD in people, with an emphasis on ethics and fairness.
-
Easier, local pulmonary rehab and social support for people with COPD in low-resource clinics
This project compares a 10-week community pulmonary rehabilitation program alone, the same program plus help with social needs, and usual care for people with moderate-to-severe COPD to see which helps people stick with rehab and feel better.
-
Improving COPD outcomes with real-world data
A doctor-scientist at a major university is using real-world information from COPD patients to understand which treatments work best, how safe they are, and whether people stick to their inhaler plans.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.